This website is for information purposes only. Use of our website is subject to your agreement to our disclaimer and terms and conditions. By closing (click "I agree") or leaving this box, you signify your agreement to these.
There is enough scientific data that upregulation of genes MME and PPARG help resolve and delay the onset of Alzheimer disease. The SSHD-MME/PPG molecules promote the function of genes MME and PPARG.
What do the genes MME and PPARG do?
In recent years there have been important advances in the understanding of the pathogenesis of Alzheimer disease. It is now well established that the principal cause of Alzheimer disease is excessive deposition of the protein beta amyloid [1] in the brain. The excess beta amyloid forms "plaques" which surround nerve cells in the brain, stopping them from working properly.
Normally, excess beta amyloid is removed by a series of proteolytic enzymes. It has now been found that the most effective beta amyloid removing proteolytic enzyme is neprolysin [2][3]. Unfortunately, the activity of neprolysin declines with age. Its activity has been found to be reduced in the brains of Alzheimer sufferers [3]. As neprolysin activation has already been proposed as an alternative approach to resolution of and protection against Alzheimer disease, a new sequence specific homeopathic DNA remedy has been developed to target the MME gene as this is the gene that encodes the enzyme neprolysin.
Alzheimer disease is also referred to as type 3 diabetes [4]. Insulin plays an important role in brain function. Alzheimer disease is also associated with insulin resistance [4]. Therefore, to help the insulin receptor work better, this remedy has been designed to also target the PPARG gene because the product of this gene plays an important role in preserving the function of the insulin receptor [5].